<DOC>
	<DOCNO>NCT00041288</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Sometimes transplanted cell reject body 's normal tissue . Cyclosporine , mycophenolate mofetil , methotrexate , tacrolimus may prevent happen . PURPOSE : Randomized phase II trial compare effectiveness fludarabine plus total-body irradiation combination chemotherapy follow donor peripheral stem cell transplantation treat patient relapse non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Comparison Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed Donor Peripheral Stem Cell Transplantation Treating Patients With Relapsed Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare 1-year overall survival rate patient relapse low-grade non-Hodgkin 's lymphoma chronic lymphocytic leukemia treat fludarabine total body irradiation v cyclophosphamide fludarabine follow allogeneic peripheral blood stem cell transplantation donor lymphocyte infusion . - Compare toxic effect regimens patient . - Compare incidence severity acute chronic graft-versus-host disease patient treat regimen . - Compare 1-year treatment-related mortality infectious complication patient treat regimen . - Compare efficacy treatment regimen , term 1-year disease-free survival , patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord disease , age ( le 55 v 55 ) , participate transplantation center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive fludarabine IV day -4 -2 . Patients undergo total body irradiation follow allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . Patients receive graft-versus-host disease ( GVHD ) prophylaxis comprise oral cyclosporine twice daily day -2 90 follow taper day 90-150 oral mycophenolate mofetil twice daily day 0-28 . - Arm II : Patients receive fludarabine IV day -6 -2 cyclophosphamide IV day -3 -2 . Patients undergo PBSCT day 0 . Patients receive GVHD prophylaxis comprise methotrexate IV day 1 , 3 , 6 , 11 tacrolimus IV continuously orally day -2 90 follow taper day 90-150 . At approximately day 180 , patient persistent disease , evidence T-cell chimerism , GVHD may receive 3 donor lymphocyte infusion administer every 1-2 month . Quality life assess baseline , 1 month , every 3 month 1 year , every 6 month 1 year . Patients follow 1 month , every 3 month 1 year , annually 2 year . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia OR Diagnosis nonHodgkin 's lymphoma Lymphoplasmacytic lymphoma Grade I follicular small cleave cell lymphoma Grade II follicular mixed cell lymphoma Diffuse small cleave cell lymphoma Small lymphocytic lymphoma Relapsed least 1 course prior therapy Availability 6/6 HLA A , B , DR identical sibling donor Nonmyeloablative transplantation candidate No clinically significant effusion ascites would preclude administration methotrexate PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 02 OR Zubrod 02 Life expectancy : At least 6 month Hematopoietic : Not specify Hepatic : Bilirubin great 3 mg/dL Renal : Creatinine great 2 mg/dL Cardiovascular : LVEF least 40 % MUGA scan echocardiogram Pulmonary : DLCO least 50 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled bacterial , viral , fungal , parasitic infection HIV1 HIV2 negative No active malignancy except basal cell skin cancer No recent history drug alcohol abuse No primary disease comorbid illness would severely limit life expectancy PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior autologous bone marrow transplantation allow disease progress transplantation No entry study part tandem autologous transplantation follow nonmyeloablative allograft protocol Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>